Eterna Therapeutics Inc (ERNA)

$0.23 -0.02 (-6.24%)
Market Cap 1.43M
Revenue (ttm) 580,000.00
Net Income (ttm) -44.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,679.31%
Debt to Equity Ratio 0.00
Volume 359,085
Avg Vol 12,707,749
Day's Range N/A - N/A
Shares Out 5.41M
Stochastic %K 48%
Beta 4.47
Analysts Hold
Price Target N/A

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 582 1199
Address:
1035 Cambridge Street, Suite 18A, Cambridge, United States
breakeven2
breakeven2 Mar. 27 at 1:54 PM
$ERNA 🙏🏼1️⃣+
0 · Reply
Russell007xx
Russell007xx Mar. 25 at 9:32 AM
$ERNA how many offerings and Rs was done by this MF Sanjeev?
0 · Reply
Russell007xx
Russell007xx Mar. 25 at 9:10 AM
$ERNA offering and Rs, don’t trust this company
0 · Reply
Jess83
Jess83 Mar. 24 at 5:27 PM
$ERNA what do you think??
1 · Reply
MrGekko2u
MrGekko2u Mar. 24 at 3:45 PM
$ERNA 👀
0 · Reply
Melting_Candlestix
Melting_Candlestix Mar. 23 at 9:52 PM
$ERNA Warrants out of the money until 0.68. LETS GO!
0 · Reply
Tusto
Tusto Mar. 23 at 6:34 PM
$ERNA RS and dilute is all this Scam does.
0 · Reply
SirHoppington
SirHoppington Mar. 23 at 6:26 PM
$ERNA she’ll bounce back. Averaged down to .24
0 · Reply
MrGekko2u
MrGekko2u Mar. 23 at 5:40 PM
$ERNA shake shake shake
0 · Reply
Russell007xx
Russell007xx Mar. 23 at 3:48 PM
$ERNA rs coming mark it
1 · Reply
Latest News on ERNA
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Feb 20, 2026, 9:05 AM EST - 5 weeks ago

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Feb 6, 2026, 9:25 AM EST - 7 weeks ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Feb 3, 2026, 8:45 AM EST - 7 weeks ago

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Jan 27, 2026, 8:45 AM EST - 2 months ago

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Jan 6, 2026, 8:15 AM EST - 2 months ago

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Dec 8, 2025, 8:30 AM EST - 3 months ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 3, 2025, 8:30 AM EST - 4 months ago

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Dec 2, 2025, 8:50 AM EST - 4 months ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov 11, 2025, 7:00 AM EST - 4 months ago

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 10, 2025, 8:35 AM EST - 4 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Nov 6, 2025, 9:15 AM EST - 5 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 29, 2025, 8:33 AM EDT - 5 months ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Oct 1, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 29, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 17, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 10, 2025, 8:30 AM EDT - 7 months ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:30 AM EDT - 7 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jul 9, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 25, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 24, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Jun 10, 2025, 9:30 AM EDT - 10 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 28, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 14, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 29, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Ernexa Therapeutics Closes New Funding Round

Apr 3, 2025, 8:55 AM EDT - 1 year ago

Ernexa Therapeutics Closes New Funding Round

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Feb 26, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 14, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Jan 9, 2025, 7:30 AM EST - 1 year ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 10, 2024, 8:00 AM EDT - 2 years ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

May 8, 2024, 9:31 AM EDT - 2 years ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Feb 20, 2024, 8:30 AM EST - 2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Dec 14, 2023, 6:56 PM EST - 2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 24, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 17, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

May 2, 2023, 7:30 AM EDT - 3 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Apr 11, 2023, 8:00 AM EDT - 3 years ago

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Mar 20, 2023, 4:10 PM EDT - 3 years ago

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

breakeven2
breakeven2 Mar. 27 at 1:54 PM
$ERNA 🙏🏼1️⃣+
0 · Reply
Russell007xx
Russell007xx Mar. 25 at 9:32 AM
$ERNA how many offerings and Rs was done by this MF Sanjeev?
0 · Reply
Russell007xx
Russell007xx Mar. 25 at 9:10 AM
$ERNA offering and Rs, don’t trust this company
0 · Reply
Jess83
Jess83 Mar. 24 at 5:27 PM
$ERNA what do you think??
1 · Reply
MrGekko2u
MrGekko2u Mar. 24 at 3:45 PM
$ERNA 👀
0 · Reply
Melting_Candlestix
Melting_Candlestix Mar. 23 at 9:52 PM
$ERNA Warrants out of the money until 0.68. LETS GO!
0 · Reply
Tusto
Tusto Mar. 23 at 6:34 PM
$ERNA RS and dilute is all this Scam does.
0 · Reply
SirHoppington
SirHoppington Mar. 23 at 6:26 PM
$ERNA she’ll bounce back. Averaged down to .24
0 · Reply
MrGekko2u
MrGekko2u Mar. 23 at 5:40 PM
$ERNA shake shake shake
0 · Reply
Russell007xx
Russell007xx Mar. 23 at 3:48 PM
$ERNA rs coming mark it
1 · Reply
tytyada
tytyada Mar. 23 at 3:25 PM
$ERNA in a sea of green . This POS is redder than Satans ballsack
0 · Reply
Cledson40
Cledson40 Mar. 23 at 3:17 PM
$ERNA Pretty ugly here
0 · Reply
Jcorey7
Jcorey7 Mar. 23 at 2:19 PM
$ERNA going to .10
0 · Reply
MrGekko2u
MrGekko2u Mar. 20 at 11:19 PM
$ERNA shake shake shake
1 · Reply
breakeven2
breakeven2 Mar. 20 at 11:02 PM
$ERNA what the F is this now (( https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/form8-k.htm )) Ernexa Therapeutics faces Nasdaq delisting notice after bid price falls below $1 for 30 days
0 · Reply
M1Tanker
M1Tanker Mar. 20 at 10:04 PM
$ERNA out for now.
0 · Reply
M1Tanker
M1Tanker Mar. 20 at 7:47 PM
$ERNA ✅️
2 · Reply
M1Tanker
M1Tanker Mar. 20 at 6:55 PM
$ERNA 🤔
0 · Reply
M1Tanker
M1Tanker Mar. 20 at 3:41 PM
$ERNA
0 · Reply
M1Tanker
M1Tanker Mar. 20 at 2:51 PM
$ERNA warrants at .68
1 · Reply
M1Tanker
M1Tanker Mar. 20 at 12:06 PM
$ERNA 🛫🛫🛫
0 · Reply
M1Tanker
M1Tanker Mar. 20 at 11:15 AM
$ERNA 🙌👇
0 · Reply